Poor
Mostly Misaligned
Patient Risk:
Medium
Summary
Only interaction-related claims about withdrawal, respiratory depression, and serotonin syndrome are partially supported by the provided label section (7 DRUG INTERACTIONS, Table 2). Most other safety details (e.g., dizziness, nausea, constipation, drowsiness, dependence/addiction/withdrawal framing), all cost/insurance/patient assistance claims, and non-interaction prescribing claims (indication, dosage forms, approval wording) cannot be verified against the provided label excerpt, leading to low overall label alignment.
Category Scores
Accurate Statements
Tramadol HCl can cause serious risks including respiratory depression.
Partially supported by 7 DRUG INTERACTIONS (Table 2), including potentially fatal respiratory depression described with CNS depressants and CYP3A4/CYP2D6 inhibitor/inducer interactions.
Tramadol HCl can cause serious risks including serotonin syndrome.
Partially supported by 7 DRUG INTERACTIONS (Table 2), including serotonin syndrome described with serotonergic drugs/MAOIs and increased risk with CYP2D6/CYP3A4 inhibitor scenarios.
The risk of serotonin syndrome with Tramadol HCl is increased when combined with other serotonergic drugs.
Partially supported by 7 DRUG INTERACTIONS (Table 2): 'concomitant use... resulted in serotonin syndrome' and examples of serotonergic drugs.
Tramadol HCl carries risks including withdrawal symptoms.
Partially supported by 7 DRUG INTERACTIONS (Table 2): opioid interactions and CYP-related changes may result in signs/symptoms of opioid withdrawal (e.g., decreased efficacy or precipitated withdrawal with certain drug interaction scenarios).
Unsupported Statements
Tramadol HCl is a prescription medication.
No provided label text supports this claim.
Tramadol HCl is approved for managing moderate to moderately severe pain.
No provided label text supports this indication wording.
Tramadol HCl is available in oral tablets and capsules.
No provided label text supports this formulation claim.
Tramadol HCl is available as extended-release products.
No provided label text supports this general availability/formulation claim (only the excerpt title references extended-release capsules in Table 2).
Tramadol HCl carries risks including dependence.
No provided label text supports this specific framing of 'dependence' within the excerpt.
Tramadol HCl carries risks including addiction.
No provided label text supports this specific framing of 'addiction' within the excerpt.
Tramadol HCl can cause side effects including dizziness.
No provided label text supports dizziness as a side effect.
Tramadol HCl can cause side effects including nausea.
No provided label text supports nausea as a side effect.
Tramadol HCl can cause side effects including constipation.
No provided label text supports constipation as a side effect (note: anticholinergic interaction mentions constipation risk, but the claim is not limited to that context and is not supported as a general adverse effect).
Tramadol HCl can cause side effects including drowsiness.
No provided label text supports drowsiness/sedation as a side effect.
Tramadol HCl can vary in cost depending on the pharmacy where it is dispensed.
No provided label text supports cost/dispensing pricing claims.
Tramadol HCl cost can differ based on formulation (e.g., immediate-release vs. extended-release).
No provided label text supports pricing differences by formulation.
Tramadol HCl cost can differ based on dosage strength.
No provided label text supports pricing differences by strength.
Tramadol HCl cost can differ based on whether a generic or brand-name version is purchased.
No provided label text supports pricing differences by generic vs brand.
Insurance coverage can impact Tramadol HCl out-of-pocket expense.
No provided label text supports insurance/coverage cost claims.
Patient assistance programs can impact Tramadol HCl out-of-pocket expense.
No provided label text supports patient assistance program cost claims.
Generic versions of Tramadol HCl are typically less expensive than brand-name counterparts.
No provided label text supports general market pricing comparisons.
Contradictions
Important Omissions
Boxed warnings and contraindications (and other critical safety sections) were not assessable because they were not provided in the available label sections excerpt.
Importance:
High
Specific dosage and administration instructions, including dosing schedules and recommended adjustments, were not assessable because the provided label excerpt did not include these sections.
Importance:
Moderate
Adverse reaction list details (e.g., dizziness/nausea/constipation/drowsiness) were not assessable because only drug interaction text was provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several critical safety-related claims are not verifiable against the provided label excerpt (e.g., dizziness/nausea/constipation/drowsiness, dependence/addiction framing). Some serious risk claims (respiratory depression, serotonin syndrome, withdrawal symptoms) are partially supported via interaction information, but overall alignment is low due to many unverified statements and lack of access to boxed warning/contraindications sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Misaligned
Primary Issue
Most claims cannot be verified against the provided FDA label excerpt (7 DRUG INTERACTIONS only). Several safety claims and all cost/coverage claims are unsupported by the provided label text.
Suggested Improvement
Restrict statements to what is supported by the provided label section; remove or qualify unverified claims (especially cost/insurance/patient assistance and general adverse-effect lists) and provide additional label sections (Indications (1), Dosage/Administration (2), Contraindications (4), Warnings/Precautions/Boxed Warning (5), Adverse Reactions (6)) for a complete label-consistent evaluation.